Generalized prurigo nodularis is a severe and widespread morphologic manifestation of chronic pruritus.1 This condition is challenging to treat and results in a high burden of disease.1 We examined the effectiveness of the interleukin (IL) 4 receptor α inhibitor dupilumab as a novel treatment option for generalized prurigo nodularis.
Beck KM, Yang EJ, Sekhon S, Bhutani T, Liao W. Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatol. Published online November 14, 2018. doi:10.1001/jamadermatol.2018.3912
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: